3 top Australian shares I'd buy for my portfolio

Some of the most attractive Australian shares are businesses that have turned specialist expertise into strong market positions.

I think that can create years of growth when the opportunity ahead is still expanding.

Here are three Australian shares that fit that description for me.

Pro Medicus Ltd (ASX: PME)

Pro Medicus helps radiologists work through enormous volumes of medical images using its Visage imaging platform.

I think the opportunity is becoming more valuable as hospitals generate more scans and healthcare networks become larger and more connected. Clinicians need images to load quickly and remain accessible across different locations, devices, and departments.

Visage can bring those images into a single cloud-based environment, helping radiologists move between cases without relying on slower or disconnected systems.

The depth of that workflow is one of the main reasons I like Pro Medicus. Once a large hospital network has adopted the platform and trained its clinicians, replacing it could become highly disruptive.

Its contracts can also run for many years, giving Pro Medicus time to strengthen the relationship and benefit as imaging volumes increase.

The shares usually command a substantial valuation, so future returns will depend on the company continuing to win major contracts and delivering strong growth. But I think its technology, customer retention, and international opportunity justify paying close attention.

Hub24 Ltd (ASX: HUB)

Financial advisers are being asked to manage more investments, reporting requirements, tax information, and client expectations.

Hub24 provides the administration platform sitting behind much of that work.

Its technology allows advisers to hold and manage different investments through one system while giving clients clearer access to their portfolios. I think that can make the platform increasingly important as advisers search for ways to serve more people without creating an equally large increase in administration.

Hub24 has been attracting substantial inflows and taking market share from older platform providers. Each new adviser relationship can also bring many client accounts onto the platform over time.

I like the scalability of the business model. As funds under administration rise, this Australian share has the potential to grow revenue faster than the cost of operating the platform.

Share market falls can reduce asset values and affect revenue, while competition from other modern platforms remains strong. Even so, I think Hub24 has the technology and reputation to keep expanding within Australia's large wealth management market.

Cochlear Ltd (ASX: COH)

A cochlear implant can begin a relationship between Cochlear and a recipient that lasts for decades.

After receiving an implant, customers may later upgrade their sound processors, replace accessories, access support, and adopt newer technology. That installed base gives Cochlear an ongoing source of demand alongside sales to new recipients.

I think the market still has considerable room to grow. Hearing loss becomes more common as populations age, yet many people who could benefit from an implant have not received one. Greater awareness, improved clinical pathways, and expanding access to healthcare could gradually bring treatment to more patients.

Cochlear also invests heavily in research and development, helping it improve sound quality, connectivity, comfort, and the overall recipient experience.

Healthcare funding decisions and competition can affect growth, and the shares are rarely inexpensive. However, I think Cochlear's brand, global distribution, clinical relationships, and large installed base make it an outstanding long-term business.

Foolish takeaway

I want companies in my portfolio that can become more valuable by deepening existing customer relationships while continuing to reach new ones.

Pro Medicus, Hub24, and Cochlear each have that opportunity, supported by specialist technology and positions that competitors would struggle to recreate quickly.

I would still consider valuation carefully and build positions gradually where prices look demanding. But with a long holding period, I think all three Australian shares offer the quality and growth potential I would want in an investment.

The post 3 top Australian shares I'd buy for my portfolio appeared first on The Motley Fool Australia.

Motley Fool contributor Grace Alvino has positions in Hub24. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Hub24. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Cochlear, Hub24, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026